- Home
- GANX vs OKYO Comparison
GANX vs OKYO Comparison
Compare GANX & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- OKYO
- Stock Information
- Founded
- GANX 2017
- OKYO 2007
- Country
- GANX United States
- OKYO United Kingdom
- Employees
- GANX N/A
- OKYO N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GANX Health Care
- OKYO Health Care
- Exchange
- GANX Nasdaq
- OKYO Nasdaq
- Market Cap
- GANX 41.9M
- OKYO 38.6M
- IPO Year
- GANX 2021
- OKYO 2022
- Fundamental
- Price
- GANX $2.28
- OKYO $1.04
- Analyst Decision
- GANX Strong Buy
- OKYO Strong Buy
- Analyst Count
- GANX 5
- OKYO 1
- Target Price
- GANX $7.60
- OKYO $7.00
- AVG Volume (30 Days)
- GANX 264.8K
- OKYO 93.8K
- Earning Date
- GANX 11-14-2024
- OKYO 01-28-2025
- Dividend Yield
- GANX N/A
- OKYO N/A
- EPS Growth
- GANX N/A
- OKYO N/A
- EPS
- GANX N/A
- OKYO N/A
- Revenue
- GANX N/A
- OKYO N/A
- Revenue This Year
- GANX N/A
- OKYO N/A
- Revenue Next Year
- GANX N/A
- OKYO N/A
- P/E Ratio
- GANX N/A
- OKYO N/A
- Revenue Growth
- GANX N/A
- OKYO N/A
- 52 Week Low
- GANX $0.89
- OKYO $0.81
- 52 Week High
- GANX $5.33
- OKYO $1.90
- Technical
- Relative Strength Index (RSI)
- GANX 57.43
- OKYO 45.08
- Support Level
- GANX $2.06
- OKYO $1.00
- Resistance Level
- GANX $2.65
- OKYO $1.35
- Average True Range (ATR)
- GANX 0.29
- OKYO 0.10
- MACD
- GANX 0.01
- OKYO -0.01
- Stochastic Oscillator
- GANX 66.36
- OKYO 11.43
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.